Table 1 Base case cost-effectiveness results without discounting and with discount rate 3 % for both costs and benefits
From: Estimating long-term clinical effectiveness and cost-effectiveness of HPV 16/18 vaccine in China
| Rurala | Screening only (A) | Screening + vaccination (B) | Difference (B-A) | ICER (CNY per QALY gained) | ICER (US$ per QALY gained) |
| Undiscounted | |||||
| Cost (CNY) | 64,386,901 | 48,641,712 | −15,745,190 | ||
| Life-years | 6,822,557 | 6,826,325 | 3768 | ||
| CC cases | 747 | 292 | −455 | ||
| CC deaths | 354 | 139 | −215 | ||
| QALYs | 6,821,273 | 6,825,826 | 4553 | −3458 | −549 |
| Discounted | |||||
| Cost (CNY) | 19,627,341 | 29,777,012 | 10,149,672 | ||
| QALYs | 2,934,012 | 2,934,905 | 893 | 11,365 | 1804 |
| Urbana | Screening only (A) | Screening + vaccination (B) | Difference (B-A) | ICER (CNY per QALY gained) | ICER (US$ per QALY gained) |
| Undiscounted | |||||
| Cost (CNY) | 92,026,104 | 62,240,211 | −29,785,893 | ||
| Life-years | 7,241,077 | 7,244,914 | 3837 | ||
| CC cases | 913 | 356 | −557 | ||
| CC deaths | 341 | 133 | −208 | ||
| QALYs | 7,239,157 | 7,244,167 | 5011 | −5944 | 944 |
| Discounted | |||||
| Cost (CNY) | 28,711,710 | 34,593,492 | 5,881,781 | ||
| QALYs | 3,001,172 | 3,002,133 | 961 | 6124 | 972 |